INTRODUCTION
During the past decade atter the successful achievement of cis-dichlorodiammine platinum(ll) (cisplatin), a number of derivatives of thiosemicarbazone, such as 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone) copper complexes (Cu-KTS), have been found to exhibit antitumour activity/1,2/by binding with DNA/3/. In addition, the copper complexes of thiosemicarbazide inactivate lambda phage infectivity and transaction by lambda DNA/4/, and inhibit the activity of RNA dependent DNA polymerase of Rous sarcoma virus/5/.
Thiosemicarbazones of l-formylisoquinoline and 2-formylpyridine and their derivatives were also demonstrated as effective against animal tumour /6,7/ at the molecular level by inhibiting the enzyme ribonucleoside diphosphate reductase and synthesis of DNA/8-10/. Many chemotherapeutic agents have also been reported to possess immunomodulatory properties/11,12/. However, the immunomodulatory potential of the metal complexes with antitumour activity has not been explored adequately. Although thiohydrazides are structurally quite similar to thiosemicarbazides, scarcity of work on the antineoplastic and immunomodulatory activity of transition metal complexes of thiohydrazides prompted us to study the (Table I) . [Cu(Htbh)zC12] was found to be most effective in the induction of tumour cell apoptosis (Fig. 3a) . (Fig. 4b) . The reversal of tumour growth associated inducation of apoptosis of hematopoietic cells by metal complexes is predicted to be due to reduction of tumour load resulting from the cytotoxic effect of metal complexes on tumour cells, leading to a decrease in the tumour associated concentration of apoptotic factors and by the direct protective effect of metal complexes on the hematopoietic cells. Although not very clear, the probability of the latter could be due to the fact that metal complexes can bind to DNA and several proteins in cells, which could result in the protective effect.
The present study shows that the Cu(ll) complexes of thiobenzhydrazide are not only active antitumour agents, but are also immunopotentiating agents, on account of their ability to reverse tumour associated immunosuppression. The importance of such work lies in the possibility that the new complexes might be more efficacious drugs for therapeutic use against tumours in view of their dual mechanism of action. 
